Repare Therapeutics (RPTX) AI Stock Analysis

• Market Cap: $58.33M
• Dividend Yield: N/A
• Average Volume (3M): 420.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: 4.58%
• EPS Growth: 10.59%
• Country: US
• Employees: 129
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -2.00
• Shares Outstanding: 42,891,403
• 10 Day Avg. Volume: 260,664
• 30 Day Avg. Volume: 420,677
• PEG Ratio: 0.08
• Price to Book (P/B): 0.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $5.00
• Price Target Upside: 267.65% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

Repare Therapeutics faces significant financial challenges and operational inefficiencies, as evidenced by revenue volatility and consistent losses. However, the company's strong cash position and low leverage provide some stability. The technical analysis highlights potential downward momentum, and the valuation is currently unfavorable due to profitability issues. Recent corporate events, including strategic restructuring and out-licensing, could potentially lead to cost savings and future revenue, offering some hope for improvement.

Positive Factors

Clinical Development

RP-3467 shows potential for significant tumor volume reductions, including clearance, in combination with PARP inhibitors.

Financial Stability

Repare's cash runway extends into late-2027, providing financial stability and possibly further extended by the new agreement.

Strategic Partnerships

Repare Therapeutics Inc announced an agreement with DCx Biotherapeutics to outlicense their preclinical discovery engines in exchange for $4M cash and other incentives.

Negative Factors

Financial Performance

Repare Therapeutics reported a net loss of $28.7 million for Q4 and $84.7 million for the fiscal year 2024.

Leadership Instability

The departure of Chief Medical Officer Maria Koehler suggests potential instability in the company's leadership.

Operational Challenges

The board's formal approval of a 75% workforce reduction indicates significant organizational changes.

Repare Therapeutics Business Overview & Revenue Model

Company Description

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

How the Company Makes Money

Repare Therapeutics generates revenue primarily through strategic partnerships and collaborations with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and potential royalties based on the successful development and commercialization of therapeutic candidates. Additionally, the company may generate revenue from licensing agreements, where it licenses its proprietary technology and intellectual property to other companies in exchange for fees and royalties. As Repare's drug candidates progress through clinical trials and potentially reach commercialization, product sales will become a direct source of revenue.

Repare Therapeutics Financial Statement Overview

Summary

Repare Therapeutics is grappling with significant financial challenges, marked by ongoing losses and revenue volatility. Despite these issues, the balance sheet shows relative stability with a strong cash position and low leverage, offering some buffer to continue operations.

Income Statement

Repare Therapeutics has shown significant revenue volatility over the years, with revenue dropping to zero in the most recent period from $51.13 million the previous year and $131.83 million two years prior. The company has consistently incurred operating losses, and negative net income, indicating ongoing profitability challenges. The EBIT and EBITDA margins are negative, reflecting operational inefficiencies. However, the company showed a brief revenue surge in 2022, which might indicate potential for recovery.

Balance Sheet

The company maintains a strong equity base relative to its liabilities, reflected in a low Debt-to-Equity ratio, which suggests stability. Despite consistent net losses, Repare's cash position remains robust, indicating prudent cash management. However, the Return on Equity is negative due to sustained net losses, which impacts overall shareholder returns negatively. The equity ratio has shown some decline but remains relatively healthy.

Cash Flow

Repare Therapeutics has faced challenges with negative free cash flow, although the cash flow from investing activities has been positive, largely due to asset management. The operating cash flow remains negative, indicating that the company is not generating enough cash from core operations to cover expenses. However, the company has managed to sustain cash reserves, which provides liquidity to continue operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
53.48M	51.13M	131.83M	7.60M	135.00K
	Gross Profit
53.48M	-80.07M	127.65M	4.26M	-1.65M
	EBIT
-93.52M	-116.22M	-19.80M	-108.66M	-54.30M
	EBITDA
-90.22M	-114.27M	-17.82M	-107.19M	-53.41M
	Net Income Common Stockholders
-84.69M	-93.80M	-29.05M	-106.91M	-53.42M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
152.79M	223.63M	343.94M	341.87M	333.71M
	Total Assets
176.51M	253.90M	364.07M	368.71M	357.09M
	Total Debt
1.93M	3.41M	5.43M	7.31M	4.00M
	Net Debt
-82.78M	-107.86M	-154.09M	-327.11M	-322.18M
	Total Liabilities
25.38M	41.82M	84.56M	80.29M	70.26M
	Stockholders Equity
151.13M	212.08M	279.52M	288.42M	286.83M
Cash Flow		Free Cash Flow
-76.44M	-129.10M	-280.00K	-87.49M	-8.32M
	Operating Cash Flow
-76.44M	-127.16M	322.00K	-85.80M	-6.08M
	Investing Cash Flow
49.47M	78.04M	-175.78M	-1.68M	-9.76M
	Financing Cash Flow
542.00K	842.00K	880.00K	95.56M	247.84M

Repare Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.36
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPTX, the sentiment is Neutral. The current price of 1.36 is above the 20-day moving average (MA) of 1.29, above the 50-day MA of 1.16, and below the 200-day MA of 2.24, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 59.21 is Neutral, neither overbought nor oversold. The STOCH value of 47.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RPTX.

Repare Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XLO	54 Neutral	$36.77M	―	-297.84%	―	―	53.92%
Sector *	52 Neutral	$5.21B	3.49	-43.30%	2.83%	14.70%	-0.24%
RPTX	51 Neutral	$58.33M	―	-46.63%	―	4.58%	10.59%
SPRO	48 Neutral	$34.11M	10.83	-89.62%	―	-71.68%	-397.61%
STTK	43 Neutral	$45.40M	―	-71.90%	―	69.65%	27.98%
OKUR	42 Neutral	$25.94M	―	-70.01%	―	―	71.57%
PRLD	35 Underperform	$49.84M	―	-81.44%	―	―	16.38%

Repare Therapeutics Corporate Events

Repare Therapeutics Out-Licenses Platforms to DCx Biotherapeutics

On May 1, 2025, Repare Therapeutics announced an agreement to out-license its discovery platforms, including intellectual property, to DCx Biotherapeutics, a Canadian biotechnology company. This strategic move allows Repare to concentrate on its clinical portfolio and reduce costs while retaining an economic interest in the technologies. The agreement includes upfront payments of $4 million, a 9.99% equity stake in DCx, and potential future milestone payments and royalties. Additionally, DCx will acquire certain Repare assets, including laboratory facilities and personnel, enhancing its capabilities in developing precision drug conjugates.

Spark’s Take on RPTX Stock

According to Spark, TipRanks’ AI Analyst, RPTX is a Neutral.

Repare Therapeutics’ overall stock score reflects significant financial and operational challenges, including revenue volatility and consistent losses. The company’s technical indicators suggest potential downward momentum, while the recent major corporate restructuring poses risks despite potential cost savings. The negative valuation due to the absence of profitability and dividends further drags the score down. However, the company’s strong cash position provides a degree of stability, preventing a lower score.

To see Spark’s full report on RPTX stock, click here.

Repare Therapeutics Announces Leadership Changes in 2025

On March 31, 2025, Repare Therapeutics announced significant leadership changes, with Lloyd Segal resigning as President and CEO, effective April 11, 2025, to pursue other opportunities. Steve Forte, the current CFO, will assume the roles of President and CEO, while Sandra Alves is promoted to Chief Accounting Officer. These changes come as Repare focuses on advancing its Phase 1 clinical trials and exploring strategic partnerships, aiming to enhance its position in the precision oncology market.

Repare Therapeutics Announces Major Reorganization in 2025

In January 2025, Repare Therapeutics announced a significant reorganization, including a 75% workforce reduction, to prioritize its Phase 1 clinical programs. This reorganization, approved on February 23, 2025, is expected to incur one-time costs of approximately $7.3 million for severance and $1.4 million for retention, with anticipated annual savings of $21 million. The departure of Chief Medical Officer Dr. Maria Koehler, effective March 31, 2025, is part of this restructuring, with severance benefits outlined. Retention bonuses are also being provided to key executives.